Recently, the attention has turned into the discovery of drugs able to interfere with specific immune checkpoints, among which programmed death-1 receptor (PD-1) and its ligand (PD-L1) have been the most studied in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.